Cargando…

A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer

BACKGROUND: This multicentre, open-label, Phase Ib/II trial evaluated the insulin-like growth factor (IGF) 1/2 neutralising antibody xentuzumab plus enzalutamide in metastatic castrate-resistant prostate cancer (mCRPC). METHODS: The trial included Phase Ib escalation and expansion parts and a random...

Descripción completa

Detalles Bibliográficos
Autores principales:	Macaulay, Valentine M., Lord, Simon, Hussain, Syed, Maroto, José Pablo, Jones, Robert Hugh, Climent, Miguel Ángel, Cook, Natalie, Lin, Chia-Chi, Wang, Shian-Shiang, Bianchini, Diletta, Bailey, Mark, Schlieker, Laura, Bogenrieder, Thomas, de Bono, Johann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491782/ https://www.ncbi.nlm.nih.gov/pubmed/37537253 http://dx.doi.org/10.1038/s41416-023-02380-1

Ejemplares similares

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
por: Schmid, Peter, et al.
Publicado: (2021)

Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
por: de Bono, Johann, et al.
Publicado: (2020)

Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies
por: Simpson, Aaron, et al.
Publicado: (2017)

A phase 1 trial of xentuzumab, an IGF‐neutralizing antibody, in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2022)

Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Sweeney, Christopher J., et al.
Publicado: (2022)

Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Aggarwal, Rahul, et al.
Publicado: (2022)

Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease
por: Suzuki, Hiroyoshi, et al.
Publicado: (2021)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
por: Park, Keunchil, et al.
Publicado: (2021)

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
por: El-Amm, Joelle, et al.
Publicado: (2013)

Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
por: Tucci, Marcello, et al.
Publicado: (2018)

Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
por: Schultz, Neil M., et al.
Publicado: (2020)

Therapeutic Targeting of the IGF Axis
por: Osher, Eliot, et al.
Publicado: (2019)

CHK1 inhibition exacerbates replication stress induced by IGF blockade
por: Wu, Xiaoning, et al.
Publicado: (2021)

Erratum for “Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide”
por: El-Amm, Joelle, et al.
Publicado: (2013)

A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer
por: Greasley, Rosa, et al.
Publicado: (2015)

Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer
por: Rhea, Logan P, et al.
Publicado: (2019)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER
por: Joshua, Anthony M., et al.
Publicado: (2022)

Clinical outcomes and survival surrogacy studies of prostate‐specific antigen declines following enzalutamide in men with metastatic castration‐resistant prostate cancer previously treated with docetaxel
por: Armstrong, Andrew J., et al.
Publicado: (2017)

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
por: Graff, Julie N, et al.
Publicado: (2020)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all
por: Maughan, Benjamin L, et al.
Publicado: (2014)

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
por: Li, Qiuhui, et al.
Publicado: (2018)

Inhibition of Rac1 reverses enzalutamide resistance in castration-resistant prostate cancer
por: Chen, Xiaoliang, et al.
Publicado: (2020)

Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
por: Luo, Mayao, et al.
Publicado: (2022)

Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
por: Bui, Cat N., et al.
Publicado: (2016)

The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer
por: Wang, Keliang, et al.
Publicado: (2020)

Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
por: Yokomizo, Akira, et al.
Publicado: (2021)

Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
por: Rana, Dikshyanta, et al.
Publicado: (2021)

Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan
por: Li, Pei-Yu, et al.
Publicado: (2022)

The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer
por: Zheng, Zeyuan, et al.
Publicado: (2022)

Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials
por: Armstrong, Andrew J., et al.
Publicado: (2019)

Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
por: Luo, Jia, et al.
Publicado: (2016)

Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer
por: Kregel, Steven, et al.
Publicado: (2016)

A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2018)

Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
por: Yokomizo, Akira, et al.
Publicado: (2022)

Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
por: Demirci, Ayşe, et al.
Publicado: (2021)

Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
por: Pu, Yeong-Shiau, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2nn7hrbfte3590qdfr73teldpt